Abstracts tagged "Autoantibody(ies)"

Abstract Number: 1153 • ACR Convergence 2024
Increased Prevalence of Myositis Specific and Associated Autoantibodies in Patients with Interstitial Lung Disease of Unknown Etiology
Vasiliki Koulouri¹, Ilektra Voulgareli², Sofia Flouda³, Nikoletta Galanopoulou⁴, Nikolaos Marketos⁵, Charalampos Skarlis⁵, Sylvia Raftopoulou⁵, Kyriaki Tavernaraki⁶, Alexia Chronaiou², Georgios Tsoukalas², Nikolaos Zias⁷, Dimitrios Boumpas⁸ and Clio Mavragani⁹, ¹Department of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Greece, Athens, Greece, ²4th Respiratory Medicine Department, Sotiria General and Chest Diseases Hospital, Athens, Greece, Athens, Greece, ³4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, ⁴10th Respiratory Medicine Department, Sotiria General and Chest Diseases Hospital, Athens, Greece, ⁵Molecular and Applied Physiology Unit, Department of Physiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece, ⁶Imaging and Interventional Radiology, Sotiria General and Chest Diseases Hospital, Athens, Greece, Athens, Greece, ⁷Respiratory Medicine Department, Athens Naval Hospital, Athens, Greece, ⁸4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, Athens, Greece, ⁹Department of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece
Background/Purpose: In recent years, connective tissue diseases (CTDs) have been increasingly recognized as a significant underlying pathology of interstitial lung diseases (ILDs). Amongst CTDs, idiopathic…
Abstract Number: 1575 • ACR Convergence 2024
Anti-U1RNP Antibodies Are Associated with a Distinct Clinical Phenotype and a Worse Survival in Patients with Systemic Sclerosis
Kevin Chevalier¹, Guillaume Chassagnon², Sarah LOUIS-LEONARD³, Pascal cohen⁴, bertrand Dunogue⁵, Alexis Régent⁶, Benjamin Thoreau⁵, Luc Mouthon⁵ and Benjamin Chaigne⁷, ¹Paris Cardiovascular Research Center, INSERM U970, Paris, France, ²Department of Radiology, Hôpital Cochin, AP-HP. Centre Université Paris Cité, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France, Paris, France, ³Sorbonne Université, INSERM, Department of Neurormyologie and Neuropathology, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ⁴National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁶National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ⁷Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Systemic sclerosis (SSc) is a rare systemic disease within the connective tissue disease (CTD) spectrum. It is characterized by microcirculatory abnormalities, skin and internal…
Abstract Number: 1801 • ACR Convergence 2024
Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus
Tania Rowley¹, Adnan R. Khan¹, Laura McLaughlin¹, Hannah Cherry¹, Farnaz Fallah-Arani¹, Yiannis Ioannou¹, Debasish Pyne² and Anthony Shock¹, ¹UCB Pharma, Slough, United Kingdom, ²Barts Health NHS Trust, London, United Kingdom
Background/Purpose: The pivotal role of CD40-CD40L interactions in systemic lupus erythematosus (SLE) pathogenesis stems from the orchestration of a range of immune and inflammatory responses…
Abstract Number: 2295 • ACR Convergence 2024
Association of Early Markers in Patients with Sjögren’s Syndrome in a Diverse Academic Cohort
Danielle Henry¹ and Schartess Culpepper Pace², ¹University of Miami at Holy Cross Health, Fort Lauderdale, FL, ²University of Miami, Pembroke Pines, FL
Background/Purpose: Sjogren’s syndrome (SS) is a heterogenous systemic inflammatory autoimmune disease characterized by sicca symptoms. It affects 0.3-1 per 1000 of the general population1. Studies…
Abstract Number: 0005 • ACR Convergence 2024
Autoantibodies Identified in Myositis-Specific Autoantibody Negative Juvenile Myositis Patients
FIONNUALA MCMORROW¹, Lisa Rider², Neil McHugh¹ and Sarah Tansley¹, ¹University of Bath, Bath, United Kingdom, ²NIEHS, NIH, Garrett Park, MD
Background/Purpose: Myositis autoantibodies are important clinical biomarkers however, around 40% of patients with juvenile myositis (JM) are classified as ‘autoantibody negative’ (1) and therefore cannot…
Abstract Number: 0285 • ACR Convergence 2024
Anti-THSD7A Antibodies Are Not Broadly Associated with IgG4-Related Disease or IgG4-Related Membranous Nephropathy
Guy Katz¹, Jesse Akaa², Grace McMahon¹, Isha Jha¹, Ian Doyle¹, Ana Fernandes¹, Zachary Wallace³, Shiv Pillai⁴, John Stone⁵ and Cory Perugino¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachussets General Hospital, Boston, MA, ³Massachusetts General Hospital, Newton, MA, ⁴Harvard Medical School, Cambridge, MA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: Membranous nephropathy (MN) is a known manifestation of IgG4-related disease (IgG4-RD). Unlike primary MN, most patients with IgG4-related MN do not have anti-phospholipase 2…
Abstract Number: 0669 • ACR Convergence 2024
Efficacy of Belimumab in Systemic Lupus Erythematosus: A Single-Centre Retrospective Study
buddhika Jayaratna¹, Pasan Serasinghe², Louise Nel³, Sahil Jain³, Shrish Sangle², Begona Lopez¹, Giovanni Sanna², Michelle Fernando¹ and David DCruz⁴, ¹Guys & St Thomas NHS Foundation Trust, London, United Kingdom, ²Guys & St Thomas NHS Foundation Trust, London, England, United Kingdom, ³Guys and St Thomas' Hospital, London, United Kingdom, ⁴The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multi-system autoimmune rheumatic disorder. Despite therapeutic advances, managing SLE remains challenging due to its complex pathogenesis and…
Abstract Number: 1154 • ACR Convergence 2024
Comparative Transcriptome Analysis of Murine Model and Human Samples in Anti-Melanoma Differentiation Associated Gene 5 Antibody-positive Rapidly Progressive Interstitial Lung Disease
Yuki Ichimura¹, Risa Konishi², Tadatsune Iida³, Kousuke Negishi⁴ and Naoko Okiyama⁵, ¹Tokyo Women’s Medical University, Tokyo, Japan, ²University of Tsukuba, Tokyo, Japan, ³Institute of Science Tokyo, Tokyo, Japan, ⁴Kawakita General Hospital, Tokyo, Japan, ⁵Institute of Science Tokyo, Toky, Japan
Background/Purpose: Anti-Melanoma differentiation associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) frequently presents with rapidly progressive interstitial lung disease (RP-ILD), leading to a high mortality rate…
Abstract Number: 1580 • ACR Convergence 2024
Overt Polyautoimmunity and Its Risk Factors in a Multicenter Cohort of Systemic Sclerosis Patients
Irene Carrión-Barberà¹, Laura Tío², Laura Triginer², María Lee², Alfredo Guillén-del Castillo³, Anna Ribes², Lidia Valencia Muntalà⁴, Jordi Monfort¹, Tarek Carlos Salman Monte:⁵, Carmen PIlar Simeón-Aznar³, Anna Pros¹ and Javier Narvaez-García⁶, ¹Hospital del Mar, Barcelona, Spain, ²Hospital del Mar Research Institute, Barcelona, Spain, ³Hospital Vall d'Hebron, Barcelona, Spain, ⁴Hospital de Bellvitge, Barcelona, Spain, ⁵Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Overt PolyA (the clinical coexistence of ≥2 autoimmune diseases (AID) that fulfill classification criteria), is a frequent phenomenon in systemic sclerosis (SSc). However, the…
Abstract Number: 1833 • ACR Convergence 2024
Immune Complexes of Antibodies Directed to Angiotensin Receptor type-1 and Extracellular Vesicles Are Unique Modulators Contributing to Systemic Sclerosis
Alexander Maximilian Hackel¹, Marieke Leiber¹, Maike Winziers¹, Gabriela Riemekasten² and Reza Akbarzadeh¹, ¹Department of Rheumatology and Clinical Immunology, University of Lübeck, Lübeck, Germany, ²University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany
Background/Purpose: Antibodies (Abs) directed against the angiotensin II type-1 receptor (AT1R) and extracellular vesicles (EVs) derived from systemic sclerosis (SSc) patients have the potential to…
Abstract Number: 2301 • ACR Convergence 2024
The Added Value of anti-Ro52 Antibody Titer in the Diagnosis of Sjögren’s Disease
Silvia Fonzetti¹, Caterina Porciani², Valentina Donati³, Davide Testa⁴, Giovanni Fulvio¹, Gaetano La Rocca¹, Inmaculada Conception Navarro García¹, Francesco Ferro⁵, Marta Mosca¹, Paola Migliorini⁶ and Chiara Baldini¹, ¹University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ²University of Pisa, Department of Clinical and Experimental Medicine - Immmunology and Allergology Unit, Pisa, Italy, ³Azienda Ospedaliero-Universitaria Pisana, Unit of Pathological Anatomy 2, Pisa, Italy, ⁴Immunology Unit, University of Pisa, Pisa, ⁵Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁶Immunology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Isolated anti-Ro52 antibodies (anti-Ro52) influence the ACR/EULAR 2016 classification criteria of Sjögren’s Disease (SD), meaning that patients with isolated anti-Ro52 positivity and abnormal salivary…
Abstract Number: 0009 • ACR Convergence 2024
Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial
Kazuki Matsuda, Shinichi Sato and Ayumi Yoshizaki, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) affects the skin and internal organs with a poor prognosis. While the exact cause remains unclear, increasing evidence indicates that B…
Abstract Number: 0308 • ACR Convergence 2024
Interstitial Lung Disease as the First Clinical Manifestation of Connective Tissue Diseases
Juan A. Meraz-Ostiz, Aina Puiggròs-Ferrer, Núria Bou, Irene Carrión-Barberà, Jordi Monfort, Carolina Pérez-García, Diana Badenes, Eva Balcells and Anna Pros-Simon, Hospital del Mar, Barcelona, Spain
Background/Purpose: Interstitial lung disease (ILD) is a common complication of connective tissue diseases (CTDs), significantly influencing prognosis and mortality. The prevalence and characteristics of new…
Abstract Number: 0673 • ACR Convergence 2024
BCMA-CD19 Compound CAR-T (cCAR) Safely Provides a Complete Humoral Reset Eliminating All Autoantibodies Resulting in Long-term Medication-Free Complete Remission Among Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients
Yong Yuan¹, Shanzhi He², Wenli Zhang³, Hongyu Zhang⁴, Vincent M DeStefano⁵, Masayuki Wada⁵, Kevin Pinz⁵, Greg Deener⁵, Yu Ma⁶, Min Wang², Fugui Li⁷, Ming Hong¹, Chanjuan Zou², Mingxia Wang², Ling Ding², Yingwen Liang⁸, Yupo Ma⁵ and Weija Wang⁹, ¹Department of Translational Medicine, Zhongshan people's Hospital, Zhongshan, China (People's Republic), ²Department of Rheumatoid Immunology, Zhongshan people's Hospital, Zhongshan, China (People's Republic), ³Department of Hematology, Peking University Shenzhen Hosptial, Shenzhen, China (People's Republic), ⁴Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China (People's Republic), ⁵iCell Gene Therapeutics, Inc., Stony Brook, NY, ⁶iCAR Bio Therapeutics Ltd, Zhongshan, China (People's Republic), ⁷Department of Translational Medicine. Zhongshan people's Hospital, Zhongshan, China (People's Republic), ⁸Department of Translational Medicine, Zhongshan's people Hospital, Zhongshan, China (People's Republic), ⁹Department of Translational Research, Zhongshan people's Hospital, Zhongshan, China (People's Republic)
Background/Purpose: Medication free complete remission (CR) has been elusive in SLE. An open label investigator-initiated trial (IIT) infused SLE/LN patients with a novel cCAR targeting…
Abstract Number: 1161 • ACR Convergence 2024
Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity
Adriana Miguel-Álvarez¹, luis M Amezcua Guerra², María L Loredo-Mendoza¹, Luis H. Silveira Torre³ and Angélica Vargas Guerrero⁴, ¹Instituto Nacional de Cardiología "Ignacio Chávez", México, Distrito Federal, Mexico, ²Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, ³Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ⁴Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico
Background/Purpose: The aim of this study is to assess if there are clinical and serological differences in patients with idiopathic inflammatory myopathies (IIM) according to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].